Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ODM-209 in mCRPC and Advanced Breast Cancer
NCT03878823Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Apr 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of ODM-209 in metastatic castration-resistant prostate cancer (mCRPC) and breast cancer (2 arms), sponsored by Orion Corporation. Primary endpoints: Maximum tolerated dose at 28 days and Dose Limiting Toxicities at 28 days. Started Apr 2019; status: completed.
02
Drugs
ODM-209
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)breast cancer
Beyond the preview
Go deeper on NCT03878823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878823.